Next year’s staggered launch of adalimumab biosimilars will mark one of the largest losses of exclusivity for a pharmaceutical company in U.S. market history.
For years, Humira has been the top-selling drug worldwide, raking in more than $20 billion in revenue last year. Manufacturers of reference biologics will be monitoring the impending upheaval, while companies with biosimilars in the pipeline will be eagerly tracking utilization data. Which drugs will secure a place on payers’ formularies, and when? And how will payers respond to this anticipated influx of Humira biosimilars?
To learn more, MMIT conducted a Rapid Response survey of 15 commercial payers representing 117 million covered lives. Most payers (53%) reported that they would likely make changes in their Humira contracting within the year, with several explaining that this transition represents a golden opportunity to recognize greater savings across the AbbVie portfolio.
For more findings and expert analysis, check out the full article on Drug Channels. And for more insight into how payers might cover and manage your drug, learn about the MMIT Strategic Launch Report.
